sphingosine-1-phosphate and Arteriosclerosis

Sphingosine-1-phosphate (S1P) has diverse biological functions acting inside cells as a second messenger to regulate cell proliferation and survival, and extracellularly, as a ligand for a group of G protein-coupled receptors (GPCRs) named the endothelial differentiation gene (EDG) family. Five closely related GPCRs of EDG family (EDG1, EDG3, EDG5, EDG6, and EDG8) have recently been identified as high-affinity S1P receptors. These receptors are coupled via Gi, Gq, G12/13, and Rho. The signaling pathways are linked to vascular cell migration, proliferation, apoptosis, intracellular Ca2+ mobilization, and expression of adhesion molecules. The formation of an atherosclerotic lesion occurs through activation of cellular events that include monocyte adhesion to the endothelium and vascular smooth muscle cell (VSMC) migration and proliferation. Thus, S1P signaling may play an important role in the pathogenesis of atherosclerotic vascular disease. This review highlights S1P signalling in vascular cells and its involvement in the formation of atherosclerotic lesions.

Topics: Animals; Apoptosis; Arteriosclerosis; Cell Division; Cell Movement; Cytokines; Humans; Lysophospholipids; Muscle, Smooth, Vascular; Phosphotransferases (Alcohol Group Acceptor); Receptors, G-Protein-Coupled; Signal Transduction; Sphingosine

Sphingosine 1-phosphate is a novel lipid mediator which exerts various actions on endothelial cells and vascular smooth muscle cells. In this review, we discuss the latest findings about the molecule in vascular biology.. It has been demonstrated that most sphingosine 1-phosphate-induced actions are mediated by the Edg-family of its receptors. Sphingosine 1-phosphate stimulates the migration and proliferation of endothelial cells and is cytoprotective towards them. The involvement of phosphoinositide 3-kinase and nitric oxide in sphingosine 1-phosphate downstream signaling in endothelial cells was recently reported, as was the enhancement of endothelial barrier integrity induced by the molecule. Sphingosine 1-phosphate inhibits migration of vascular smooth muscle cells and this inhibition was reported to be mediated by inhibition of Rac. Sphingosine 1-phosphate is concentrated in the lipoprotein fraction in plasma, and high-density lipoprotein exerted endothelial cytoprotection through its component of this molecule.. Sphingosine 1-phosphate might play a critical role in the development of atherosclerosis.

Topics: Animals; Arteriosclerosis; Endothelium, Vascular; Humans; Lysophospholipids; Muscle, Smooth, Vascular; Signal Transduction; Sphingosine

Topics: Animals; Apoptosis; Arteriosclerosis; Ceramides; Cholesterol; Humans; Lysophospholipids; Phosphotransferases (Alcohol Group Acceptor); Signal Transduction; Sphingomyelins; Sphingosine; Transferases (Other Substituted Phosphate Groups)

Topics: Animals; Arteriosclerosis; Endothelium, Vascular; Humans; Lipoproteins, HDL; Lysophospholipids; Protein Binding; Sphingosine

Sphingosine 1-phosphate (S1P) concentration in plasma and serum has been estimated to be within 200-900 nM. Among plasma and serum components, S1P is concentrated in lipoprotein fractions with a rank order of high-density lipoprotein (HDL)>low-density lipoprotein (LDL)>very low-density lipoprotein (VLDL)>lipoprotein-deficient plasma (LPDP) when expressed as the per unit amount of protein. It is well known that LDL, especially oxidized LDL, is closely correlated and HDL is inversely correlated, with the risk of cardiovascular disease, such as atherosclerosis. Evidence was presented that a part of HDL-induced actions previously reported are mediated by the lipoprotein-associated S1P. Furthermore, S1P content in LDL was markedly decreased during its oxidation. This paper will discuss whether S1P is an atherogenic mediator or an anti-atherogenic mediator.

Topics: Animals; Arteriosclerosis; Carrier Proteins; Humans; Lipoproteins; Lysophospholipids; Sphingosine

This review discusses multiple effects of sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) on endothelial cells and proposes that S1P and LPA are important regulators of the vascular system. Two physiologic sources of S1P and LPA are platelets and lipoproteins. S1P is an inducer of angiogenesis in vivo whereas LPA is not. S1P and LPA act through endothelial cell surface Edg receptors. S1P stimulates endothelial cell migration, but inhibits migration of most nonendothelial cells. Edg1 and Edg3 receptors, working through G(i), play an important role in regulation of S1P-stimulated endothelial cell migration. LPA effects on endothelial cells are more restricted than the effects of S1P on endothelial cells. LPA stimulates migration of certain endothelial cells on certain extracellular matrix proteins. However, LPA acts like S1P in its effects on the endothelial cell cytoskeleton, proliferation, cell-cell adhesion molecule expression, and vascular permeability. LPA receptors on endothelial cells are likely Edg2 and Edg4. Future studies should better delineate the roles of Edg receptors and downstream pathways on effects of extracellular S1P and LPA and the contributions of intracellularly generated S1P and nitric oxide (NO).

Topics: Animals; Arteriosclerosis; Cell Survival; Endothelium, Vascular; Humans; Lysophospholipids; Models, Biological; Neovascularization, Physiologic; Sphingosine

Lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are potent bioactive phospholipids with specific and multiple effects on blood cells and cells of the vessel wall. Released by activated platelets, LPA and S1P mediate physiological wound healing processes such as vascular repair. Evidence is accumulating that these lipid mediators can, however, under certain conditions become athero- and thrombogenic molecules that might aggravate cardiovascular disease. For example, LPA present in minimally modified LDL and within the intima of atherosclerotic lesions may play a role in the early phase of atherosclerosis by inducing barrier dysfunction and increased monocyte adhesion of the endothelium, as well as in the late phase by triggering platelet activation and intra-arterial thrombus formation upon rupture of the atherosclerotic plaque. Moreover, LPA and S1P, by stimulating the proliferation of fibroblasts and by enhancing the survival of inflammatory cells are likely to play a central role in the excessive fibroproliferative and inflammatory response to vascular injury that characterizes the progression of atherosclerosis. Furthermore, LPA can cause the phenotypic dedifferentiation of medial vascular smooth muscle cells, and S1P is able to stimulate the migration and proliferation of intimal vascular smooth muscle cells; both processes ultimately lead to the formation of the neointima. Most importantly, as LPA and S1P bind to and activate multiple G-protein receptors, it emerges that the beneficial or harmful action of LPA and S1P are critically dependent on the expression profile of their receptor subtypes and their coupling to different signal transduction pathways in the target cells. By targeting specific subtypes of LPA and S1P receptors in selective cells of the vascular wall and blood, new strategies for the prevention and therapy of cardiovascular diseases can be envisioned.

Topics: Animals; Arteriosclerosis; Cell Membrane Permeability; Endothelium, Vascular; Humans; Lysophospholipids; Platelet Activation; Sphingosine; Thrombosis

Sphingosine 1-phosphate (S1P), one of the sphingolipid metabolites, has been shown to participate in a variety of cellular responses including proliferation, differentiation, adhesion, motility, and apoptosis. These cellular responses elicited by S1P were first thought to be mediated through an intracellular target(s), but extracellular mechanisms through G-protein-coupled S1P receptors have also been suggested. In addition to the studies examining the functions of the lipid on the cells and tissues, the measurement of the lipid concentration is also important for understanding the physiological and pathophysiological roles of the lipid. We have recently developed a novel quantitative method for measurement of S1P, which was based on the competition of S1P in the samples with the labeled S1P on the S1P receptor Edg-1. Here, we compared our method with previously published ones in several points including specificity and simplicity. We further presented our recent results obtained by using this novel quantitative method and finally mentioned the prospects of the S1P measurement in lipid research, especially in relation to several disorders.

Topics: Arteriosclerosis; Cell Physiological Phenomena; Humans; Lipoproteins; Lysophospholipids; Radioligand Assay; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine

Sphingosine 1-phosphate (S1P) is stored in and released from platelets in response to cell activation. However, recent studies show that it is also released from a number of cell types, where it can function as a paracrine/autocrine signal to regulate cell proliferation, differentiation, survival, and motility. This review discusses the role of S1P in cellular regulation, both at the molecular level and in terms of health and disease. The main biochemical routes for S1P synthesis (sphingosine kinase) and degradation (S1P lyase and S1P phosphatase) are described. The major focus is on the ability of S1P to bind to a novel family of G-protein-coupled receptors (endothelial differentiation gene [EDG]-1, -3, -5, -6, and -8) to elicit signal transduction (via G(q)-, G(i)-, G(12)-, G(13)-, and Rho-dependent routes). Effector pathways regulated by S1P are divergent, such as extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, phospholipases C and D, adenylyl cyclase, and focal adhesion kinase, and occur in multiple cell types, such as immune cells, neurones, smooth muscle, etc. This provides a molecular basis for the ability of S1P to act as a pleiotropic bioactive lipid with an important role in cellular regulation. We also give an account of the expanding role for S1P in health and disease; in particular, with regard to its role in atherosclerosis, angiogenesis, cancer, and inflammation. Finally, we describe future directions for S1P research and novel approaches whereby S1P signalling can be manipulated for therapeutic intervention in disease.

Topics: Aldehyde-Lyases; Animals; Arteriosclerosis; Cell Differentiation; Endothelium; Gene Expression Regulation; GTP-Binding Protein Regulators; Humans; Inflammation; Lysophospholipids; Neoplasms; Neovascularization, Pathologic; Phosphotransferases (Alcohol Group Acceptor); Signal Transduction; Sphingosine

Transplant arteriosclerosis is a major cause of late intestinal allograft dysfunction. However, little is known about the immunologic and molecular mechanisms underlying it, and no effective treatment is available. This study aimed to investigate the role of sphingosine kinase 1 (SPHK1)/sphingosine-1-phosphate (S1P) in transplant arteriosclerosis and find out whether fish oil (FO) attenuates allograft arteriosclerosis through S1P signaling.. A rat model with orthotopic intestinal transplantation was conducted in this study. Animals received daily FO supplementation after intestinal transplant. The allogeneic recipients by phosphate-buffered saline or corn oil treatment served as controls. The allograft arteriosclerosis was characterized, and the expression of SPHK1 and S1P receptors (S1P₁, S1P₂, and S1P₃) was determined on day 190 posttransplant.. The allogeneic controls presented transplant vasculopathy in mesenteric vessels, including intimal thickening, fibrosis, and leukocyte infiltration. The transplant arteriosclerosis was markedly reduced in FO-fed animals. The pression of SPHK1 and its activity were significantly augmented, and the expression of S1P₁ and S1P₃ messenger RNA was up-regulated in the allogeneic controls. FO supplementation suppressed the activation of SPHK1 and led to a decrease in the expression of S1P₁ and S1P₃ in these tissues in transplant arteriosclerosis.. These results demonstrate that the activation of SPHK1/S1P signaling plays a possible role in the pathogenesis of transplant arteriosclerosis. The reduction of allograft arteriosclerosis by FO may be associated with down-regulation of SPHK1/S1P signaling. Understanding the role of FO for SPHK1/S1P may help us to identify considerable therapeutic targets for transplant arteriosclerosis.

Topics: Animals; Arteriosclerosis; Cell Movement; Cell Proliferation; Endothelial Cells; Fish Oils; Intestines; Lysophospholipids; Male; Phosphotransferases (Alcohol Group Acceptor); Postoperative Complications; Rats; Rats, Inbred F344; Rats, Inbred Lew; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Transplantation, Homologous

Gα(12/13) play a role in oncogenic transformation and tumor growth. Cysteine-rich protein 61 (CYR61) is a growth-factor-inducible angiogenic factor. In view of potential overlapping functions between Gα(12/13) and CYR61, this study investigated the role of these G proteins in CYR61 induction in association with hyperplastic vascular abnormality.. Overexpression of activated Gα(12) or Gα(13) induced CYR61 expression in vascular smooth muscle cells (VSMCs). Gene knockdown and knockout experiments revealed that sphingosine-1-phosphate (S1P) treatment induced CYR61 via Gα(12/13). JunD/activator protein-1 (AP-1) was identified as a transcription factor required for CYR61 transactivation by S1P. Deficiencies in Gα(12/13) abrogated AP-1 activation and AP-1-mediated CYR61 induction. c-Jun N-terminal kinase was responsible for CYR61 induction. Moreover, deficiencies of Gα(12/13) abolished c-Jun N-terminal kinase-dependent CYR61 induction by S1P. N-acetyl-l-cysteine or NADPH oxidase inhibitor treatment reversed CYR61 induction by S1P, indicating that reactive oxygen species are responsible for this process. The levels of Gα(12/13) were increased within thickened intimas and medias in wire-injured mouse femoral arteries, which was accompanied by simultaneous CYR61 induction. Moreover, Gα(12/13) and CYR61 were costained in the arteriosclerotic lesions immediately adjacent to human tumor tissues.. Gα(12/13) regulate AP-1-dependent CYR61 induction in VSMCs and promote VSMC migration, and they are upregulated with CYR61 in arteriosclerotic lesions.

Topics: Aged; Animals; Arteriosclerosis; Cell Movement; Cysteine-Rich Protein 61; Disease Models, Animal; Enzyme Activation; Female; GTP-Binding Protein alpha Subunits, G12-G13; HEK293 Cells; Humans; Hyperplasia; JNK Mitogen-Activated Protein Kinases; Lysophospholipids; Male; Mice; Mice, Inbred ICR; Mice, Knockout; Middle Aged; Muscle, Smooth, Vascular; Mutation; NADPH Oxidases; Promoter Regions, Genetic; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA Interference; Signal Transduction; Sphingosine; Transcription Factor AP-1; Transfection; Tunica Intima; Up-Regulation

Sphingolipids play a very important role in cell membrane formation, signal transduction, and plasma lipoprotein metabolism, all of which may well have an impact on the development of atherosclerosis. To investigate the relationship between sphingolipid metabolism and atherosclerosis, we utilized myriocin to inhibit mouse serine palmitoyl-CoA transferase (SPT), the key enzyme for sphingolipid biosynthesis. We injected 8-week-old apoE-deficient mice with myriocin (0.3 mg/kg/every other day, intraperitoneal) for 60 days. On a chow diet, myriocin treatment caused a significant decrease (50%) in liver SPT activity (p < 0.001), significant decreases in plasma sphingomyelin, ceramide, and sphingosine-1-phosphate levels (54, 32, and 73%, respectively) (p < 0.0001), and a significant increase in plasma phosphatidylcholine levels (91%) (p < 0.0001). Plasma total cholesterol and triglyceride levels demonstrated no significant changes, but there was a significant decrease in atherosclerotic lesion area (42% in root and 36% in en face assays) (p < 0.01). On a high fat diet, myriocin treatment caused marked decreases in plasma sphingomyelin, ceramide, and sphingosine-1-phosphate levels (59, 66, and 81%, respectively) (p < 0.0001), and a marked increase in plasma phosphatidylcholine levels (100%) (p < 0.0001). Total cholesterol and triglyceride demonstrated no significant changes, but there was a significant decrease in atherosclerotic lesion area (39% in root and 37% in en face assays) (p < 0.01). These results indicate that, apart from cholesterol levels, sphingolipids have an effect on atherosclerotic development and that SPT has proatherogenic properties. Thus, inhibition of SPT activity could be an alternative treatment for atherosclerosis.

Topics: Acyltransferases; Animal Feed; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Ceramides; Cholesterol; Fatty Acids, Monounsaturated; Immunosuppressive Agents; Lipid Metabolism; Lipids; Lipoproteins; Lysophospholipids; Mass Spectrometry; Mice; Mice, Knockout; Phosphatidylcholines; Serine C-Palmitoyltransferase; Signal Transduction; Sphingolipids; Sphingosine; Time Factors; Triglycerides

Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (SIP) are potent bioactive lipids with specific and multiple effects on cells of the vessel wall and blood platelets. In this paper we suggest that these lipid molecules are involved in atherogenesis, pathological vasoconstriction, plaque rupture, and intravascular thrombus formation, which leads us to propose new strategies for the prevention and therapy of cardiovascular diseases. The conclusions are hypothetical, in that the studies were so far mainly carried out on isolated cells or cultured cells in vitro and the results were extrapolated to the situation in vivo.

Topics: Arteriosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; Lysophospholipids; Phosphorylation; Signal Transduction; Sphingosine; Thrombosis

The ability of high density lipoproteins (HDL) to inhibit cytokine-induced adhesion molecule expression has been demonstrated in their protective function against the development of atherosclerosis and associated coronary heart disease. A key event in atherogenesis is endothelial activation induced by a variety of stimuli such as tumor necrosis factor-alpha (TNF), resulting in the expression of various adhesion proteins. We have recently reported that sphingosine 1-phosphate, generated by sphingosine kinase activation, is a key molecule in mediating TNF-induced adhesion protein expression. We now show that HDL profoundly inhibit TNF-stimulated sphingosine kinase activity in endothelial cells resulting in a decrease in sphingosine 1-phosphate production and adhesion protein expression. HDL also reduced TNF-mediated activation of extracellular signal-regulated kinases and NF-kappaB signaling cascades. Furthermore, HDL enhanced the cellular levels of ceramide which in turn inhibits endothelial activation. Thus, the regulation of sphingolipid signaling in endothelial cells by HDL provides a novel insight into the mechanism of protection against atherosclerosis.

Topics: Arteriosclerosis; Cell Adhesion Molecules; Cells, Cultured; Ceramides; E-Selectin; Endothelium, Vascular; Enzyme Activation; Humans; Lipoproteins, HDL; Lysophospholipids; Mitogen-Activated Protein Kinases; NF-kappa B; Phosphotransferases (Alcohol Group Acceptor); Signal Transduction; Sphingomyelins; Sphingosine; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1